Interleukin-6 Associated with Insulin Resistance in Non-Diabetic Predialysis Chronic Kidney Disease Patients
Rendy Revandana Bramantya, Chandra Irwanadi Mohani, Soebagijo Adi Soelistijo
IL-6 is a proinflammatory cytokine that is commonly obtained in chronic kidney disease (CKD) patients and has a role in insulin resistance. This study aimed to determine the correlation between IL-6 and insulin resistance in non-diabetic predialysis CKD patients. Methods: The cross sectional observational analytic study involved 35 subjects as CKD patients with non-diabetic predialysis who were diagnosed based on KDOQI criteria. Examination of serum IL-6 levels was carried out using the ELISA method, and insulin resistance was calculated using the HOMA-IR formula. Results: Thirty-five non-diabetic predialysis CKD patients were enrolled in this study, consisting of 25 (71.4%) males and 10 (28.6%) females. The mean age was 52.5 years (range of 31-60 years). Subjects with stage 3 CKD was 11 patients (31.4%), stage 4 was 6 patients (17.14%), and stage 5 was 18 patients (51.43%). HOMA-IR level was 1.61±1.13 with a median of 1.15 (0.32-4.59). Levels of IL-6 had a mean of 9.03 ± 7.01 and a median of 8.13 (1.01-24.82). There was a significant positive correlation between IL-6 levels and insulin resistance (p = 0.031, r = 0.366) Conclusion: Serum IL-6 levels had a significant positive correlation with insulin resistance in CKD patients with non-diabetic predialysis.